[Gene therapy to cure HIV infection].

Thérapie génique pour guérir l’infection par le VIH.
HIV-1 U1 interfering RNA aptamers gene therapy ribozymes short hairpin RNAs

Journal

Virologie (Montrouge, France)
ISSN: 1267-8694
Titre abrégé: Virologie (Montrouge)
Pays: France
ID NLM: 9802575

Informations de publication

Date de publication:
01 Oct 2023
Historique:
medline: 23 11 2023
pubmed: 22 11 2023
entrez: 22 11 2023
Statut: ppublish

Résumé

To date, the only intervention that has cured HIV infection has been bone marrow transplants from HIV-resistant donors to HIV-infected recipients. This approach has been used to both cure hematological malignancies and HIV infection, but it cannot be widely adopted due to the high risk of mortality associated with cell transplants between individuals. To overcome this limitation, several approaches have been developed to generate HIV resistance using gene therapy in an infected individual's own cells. With the growing arsenal of effective methods to generate HIV-resistant cells, a safe and effective combination gene therapy approach to cure HIV infection is fast approaching. Here, we review several gene therapy-based methods to generate HIV-resistant cells including the expression of antiviral genes, genome editing, and transcriptional gene silencing. Their varied mechanisms, advantages, and disadvantages are discussed, and perspectives are provided for how they may be combined to design an effective gene therapy for HIV.

Identifiants

pubmed: 37991319
pii: vir.2023.1021
doi: 10.1684/vir.2023.1021
doi:

Types de publication

Review English Abstract Journal Article

Langues

fre

Sous-ensembles de citation

IM

Pagination

284-306

Auteurs

Ryan P Goguen (RP)

Institut Lady Davis de recherches médicales, Montréal, Québec, H3T 1E2, Canada, Département de Microbiologie-Immunologie, Université McGill, Montréal, Québec, H3A 0G4, Canada.

Michelle J Chen (MJ)

Institut Lady Davis de recherches médicales, Montréal, Québec, H3T 1E2, Canada, Département de Médecine, division de Médecine expérimentale, Université McGill, Montréal, Québec, H3A 0G4, Canada.

Owen R S Dunkley (ORS)

Institut Lady Davis de recherches médicales, Montréal, Québec, H3T 1E2, Canada, Département de Médecine, division de Médecine expérimentale, Université McGill, Montréal, Québec, H3A 0G4, Canada.

Anne Gatignol (A)

Institut Lady Davis de recherches médicales, Montréal, Québec, H3T 1E2, Canada, Département de Microbiologie-Immunologie, Université McGill, Montréal, Québec, H3A 0G4, Canada, Département de Médecine, division de Médecine expérimentale, Université McGill, Montréal, Québec, H3A 0G4, Canada.

Robert J Scarborough (RJ)

Institut Lady Davis de recherches médicales, Montréal, Québec, H3T 1E2, Canada, Département de Microbiologie-Immunologie, Université McGill, Montréal, Québec, H3A 0G4, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH